Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metronidazole benzoate is a benzoate ester derivative of metronidazole, formed by the condensation of benzoic acid with the hydroxy group of metronidazole. It appears as a crystalline, white or slightly yellowish powder and is less bitter than standard metronidazole, making it suitable for oral suspensions, especially in pediatric and veterinary use[1][5]. Metronidazole (the active moiety) is an antibiotic and antiprotozoal agent belonging to the nitroimidazole class. Its mechanism involves diffusion into anaerobic bacteria and protozoa where it is reduced to a nitroso free radical that disrupts DNA structure, leading to cell death[3]. Metronidazole benzoate is used primarily for treating bacterial infections (especially anaerobic bacteria) and intestinal parasites such as amoebiasis and giardiasis[1][4]. It may also be used in veterinary medicine when compounded due to its improved palatability over standard formulations[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metronidazole benzoate.